Corcept Therapeutics

Medical Science Liaison/Sr. Medical Science Liaison, Oncology - North Central Region

Remote

Not SpecifiedCompensation
Senior (5 to 8 years), Expert & Leadership (9+ years)Experience Level
Full TimeJob Type
UnknownVisa
Pharmaceuticals, Biotechnology, HealthcareIndustries

Requirements

Candidates should possess strong scientific oncology acumen, including knowledge of therapeutic landscapes, NCCN guidelines, clinical trial data, oncology cooperative groups, and NCI/NCCN cancer centers. They must exemplify intellectual curiosity, adaptability to change, teamwork, strong communication, results-orientation, decision-making skills, and clinical/scientific expertise. A strong business acumen with working knowledge of drug development processes across research, development, clinical operations, biostatistics, regulatory, and commercial functions is also required. Approximately 50-60% travel is expected.

Responsibilities

The Medical Science Liaison will engage in clinically meaningful scientific discussions with thought leaders in gynecological oncology and other malignancies to enhance their knowledge of Corcept and cortisol modulation in oncology. They will educate healthcare professionals on disease states where cortisol modulation may play a role, provide scientific exchange on Corcept's data and development plans, and develop strong relationships with thought leaders, patient advocacy organizations, and oncology associations. Responsibilities include capturing, analyzing, and communicating insights from the medical and scientific community to inform company decisions, supporting company-sponsored clinical trials, investigator-initiated studies, scientific communications, publications, education, advisory boards, and congresses. Maintaining high standards of scientific, clinical, and technical expertise in relevant therapeutic areas and demonstrating teamwork and collaboration within Medical Affairs and cross-functionally are also key duties.

Skills

Cortisol modulation
Glucocorticoid receptor (GR)
Oncology
Gynecological oncology
Thought leader engagement
Insight gathering
Scientific education
Clinical discussions
Healthcare professional education

Corcept Therapeutics

Develops cortisol modulators for medical conditions

About Corcept Therapeutics

Corcept Therapeutics focuses on developing treatments that regulate cortisol levels in the body, which is important for managing various health issues. Their main product, Korlym, is used to treat Cushing's syndrome, a condition caused by too much cortisol. Korlym was approved by the FDA in 2012 and is the first medication specifically for this disorder. Corcept stands out from competitors by having a strong emphasis on research and development, having discovered over 1,000 unique cortisol modulators. The company aims to expand its range of treatments while also providing educational resources to healthcare professionals and patients to improve understanding and care for cortisol-related conditions.

Menlo Park, CaliforniaHeadquarters
1998Year Founded
$39.7MTotal Funding
IPOCompany Stage
Biotechnology, HealthcareIndustries
201-500Employees

Benefits

Remote Work Options
Flexible Work Hours

Risks

Teva's antitrust lawsuit could lead to legal expenses and market share loss.
Heavy reliance on Korlym makes Corcept vulnerable to market fluctuations.
Recent investments may pressure Corcept for short-term financial performance, impacting R&D.

Differentiation

Corcept specializes in cortisol modulation, a niche with few direct competitors.
Korlym is the first FDA-approved treatment for Cushing's syndrome, a significant market advantage.
Corcept's extensive R&D has led to the discovery of over 1,000 selective cortisol modulators.

Upsides

Increased interest in cortisol therapies for mental health boosts Corcept's R&D prospects.
Advancements in drug delivery systems could enhance Corcept's product efficacy.
The FDA's fast-track designation supports Corcept's innovative cortisol-related treatments.

Land your dream remote job 3x faster with AI